<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The aim of the article is to gather and summarize the published data about the incidence, course of illness, treatment possibilities and complications of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disorders</z:e> in patients with <z:e sem="disease" ids="C0026709" disease_type="Disease or Syndrome" abbrv="">mucopolysaccharidosis type VI</z:e> (MPS VI) also known as <z:e sem="disease" ids="C0026709" disease_type="Disease or Syndrome" abbrv="">Maroteaux-Lamy syndrome</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>MPS VI is a lysosomal storage disorder caused by deficient activity of N-acetylogalactosamine-4-sulfatase leading to progressive intracellular accumulation of <z:chebi fb="0" ids="18085">glycosaminoglycans</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>The relatively low birth prevalence ranging from 1 in 43,000 to 1 in 1.5 million births mirrors the limited descriptions of the <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disorders</z:e> in the medical literature </plain></SENT>
<SENT sid="3" pm="."><plain>Patients with MPS VI can be specifically treated with enzyme replacement therapy </plain></SENT>
<SENT sid="4" pm="."><plain>Extra-cardiac features include <z:hpo ids='HP_0001510'>growth retardation</z:hpo>, <z:hpo ids='HP_0000280'>coarse facial features</z:hpo>, <z:hpo ids='HP_0001387'>stiff joints</z:hpo>, skeletal malformations (<z:hpo ids='HP_0000943'>dysostosis multiplex</z:hpo>), respiratory problems, <z:hpo ids='HP_0007957'>corneal clouding</z:hpo>, and <z:hpo ids='HP_0001433'>hepatosplenomegaly</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>The clinical presentation varies considerably, however the development of <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">heart disease</z:e> and cardiac dysfunction is a serious problem in the majority of patients </plain></SENT>
<SENT sid="6" pm="."><plain>The most characteristic cardiac presentation is valvular disease, while other MPS VI patients also develop <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo>, <z:e sem="disease" ids="C0016038" disease_type="Disease or Syndrome" abbrv="">fibroelastosis</z:e>, <z:hpo ids='HP_0002092'>pulmonary hypertension</z:hpo>, cardiac conduction system disorders and other complications </plain></SENT>
<SENT sid="7" pm="."><plain>There are also reports on <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001635'>heart failure</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Early cardiovascular manifestation may escape detection since <z:hpo ids='HP_0001387'>joint stiffness</z:hpo> or skeletal malformations limit maximal exercise levels and respiratory system involvement may mask the underlining <z:hpo ids='HP_0001635'>cardiac insufficiency</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>A correct and timely diagnosis offers the possibility of disease-specific treatment leading to sustained clinical benefits for cardiac and non-cardiac MPS VI manifestations </plain></SENT>
</text></document>